Role of C-reactive protein in cerebrovascular disease: a critical review

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121(7), 948–954 (2010).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F. Neuroinflammation. An important role in the pathogenic pathways of cerebral ischemia. Nova Science Publishers, Inc., NY, USA (2009).
   Google Scholar
• Wang J, Dore S. Inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab.27(5), 894–908 (2007).
   PubMed Web of Science ®Google Scholar
• Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ. Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg. Clin. N. Am.21(2), 365–379 (2010).
   PubMed Web of Science ®Google Scholar
• Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol. Immunol.38(2–3), 189–197 (2001).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Pattern recognition by pentraxins. Adv. Exp. Med. Biol.653, 98–116 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure7(2), 169–177 (1999).
   PubMed Web of Science ®Google Scholar
• Shrive AK, Cheetham GM, Holden D et al. Three dimensional structure of human C-reactive protein. Nat. Struct. Biol.3(4), 346–354 (1996).
   PubMedGoogle Scholar
• Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. J. Mol. Recognit.24(2), 371–377 (2011).
   PubMedGoogle Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest.111(12), 1805–1812 (2003).
   PubMed Web of Science ®Google Scholar
• Das T, Mandal C. Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions. Glycoconj. J.20(9), 537–543 (2004).
   PubMed Web of Science ®Google Scholar
• Das T, Sen AK, Kempf T, Pramanik SR, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem. J.373(Pt 2), 345–355 (2003).
   PubMedGoogle Scholar
• Lu J, Marnell LL, Marjon KD, Mold C, du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature456(7224), 989–992 (2008).
   PubMed Web of Science ®Google Scholar
• Duncan AR, Winter G. The binding site for C1q on IgG. Nature332(6166), 738–740 (1988).
   PubMed Web of Science ®Google Scholar
• Mcgrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J. Immunol.176(5), 2950–2957 (2006).
   PubMedGoogle Scholar
• Gaboriaud C, Juanhuix J, Gruez A et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem.278(47), 46974–46982 (2003).
   PubMed Web of Science ®Google Scholar
• Kinoshita CM, Ying SC, Hugli TE et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry28(25), 9840–9848 (1989).
   PubMed Web of Science ®Google Scholar
• Bang R, Marnell L, Mold C et al. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis. J. Biol. Chem.280(26), 25095–25102 (2005).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C-reactive protein. J. Immunol.166(6), 3998–4004 (2001).
   PubMed Web of Science ®Google Scholar
• Ji SR, Wu Y, Zhu L et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J.21(1), 284–294 (2007).
   PubMedGoogle Scholar
• Eisenhardt SU, Habersberger J, Murphy A et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res.105(2), 128–137 (2009).
   PubMed Web of Science ®Google Scholar
• Ying SC, Gewurz H, Kinoshita CM, Potempa LA, Siegel JN. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J. Immunol.143(1), 221–228 (1989).
   PubMedGoogle Scholar
• Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation109(16), 2016–2022 (2004).
   PubMed Web of Science ®Google Scholar
• Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation110(17), 2713–2720 (2004).
   PubMedGoogle Scholar
• Khreiss T, Jozsef L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ. Res.97(7), 690–697 (2005).
   PubMed Web of Science ®Google Scholar
• Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler. Thromb. Vasc. Biol.28(12), 2239–2246 (2008).
   PubMed Web of Science ®Google Scholar
• Rees RF, Gewurz H, Siegel JN, Coon J, Potempa LA. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin. Immunol. Immunopathol.48(1), 95–107 (1988).
   PubMedGoogle Scholar
• Slevin M, Krupinski J. A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease? Histol. Histopathol.24(11), 1473–1478 (2009).
   PubMedGoogle Scholar
• Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J. Immunol.126(5), 1820–1825 (1981).
   PubMed Web of Science ®Google Scholar
• Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, Van Den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol. Today18(3), 111–115 (1997).
   PubMedGoogle Scholar
• Li YP, Mold C, Du Clos TW. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J. Immunol.152(6), 2995–3005 (1994).
   PubMedGoogle Scholar
• Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl Acad. Sci. USA99(20), 13043–13048 (2002).
   PubMed Web of Science ®Google Scholar
• Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med.192(9), 1353–1364 (2000).
   PubMed Web of Science ®Google Scholar
• Hart SP, Alexander KM, Maccall SM, Dransfield I. C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages. J. Inflamm. (Lond.)2, 5 (2005).
   PubMedGoogle Scholar
• Black S, Kushner I, Samols D. C-reactive Protein. J. Biol. Chem.279(47), 48487–48490 (2004).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int. Rev. Exp. Pathol.27, 83–111 (1985).
   PubMedGoogle Scholar
• Rowe IF, Soutar AK, Trayner IM, Thompson GR, Pepys MB. Circulating human C-reactive protein binds very low density lipoproteins. Clin. Exp. Immunol.58(1), 237–244 (1984).
   PubMedGoogle Scholar
• Vigo C. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J. Biol. Chem.260(6), 3418–3422 (1985).
   PubMed Web of Science ®Google Scholar
• Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J. Biol. Chem.259(11), 7311–7316 (1984).
   PubMedGoogle Scholar
• Du Clos TW, Marnell L, Zlock LR, Burlingame RW. Analysis of the binding of C-reactive protein to chromatin subunits. J. Immunol.146(4), 1220–1225 (1991).
   PubMedGoogle Scholar
• Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol. Biol. Rep.23(3–4), 253–260 (1996).
   PubMedGoogle Scholar
• Du Clos TW. Function of C-reactive protein. Ann. Med.32(4), 274–278 (2000).
   PubMed Web of Science ®Google Scholar
• Black S, Agrawal A, Samols D. The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol. Immunol.39(16), 1045–1054 (2003).
   PubMed Web of Science ®Google Scholar
• Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology42(1–3), 23–30 (1999).
   PubMedGoogle Scholar
• Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin. Chem. Lab. Med.37(3), 265–270 (1999).
   PubMedGoogle Scholar
• Volanakis JE, Narkates AJ. Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol. Immunol.20(11), 1201–1207 (1983).
   PubMedGoogle Scholar
• Li SH, Szmitko PE, Weisel RD et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation109(7), 833–836 (2004).
   PubMedGoogle Scholar
• Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem.285(2), 1053–1065 (2010).
   PubMedGoogle Scholar
• Hakobyan S, Harris CL, Van Den Berg CW et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J. Biol. Chem.283(45), 30451–30460 (2008).
   PubMedGoogle Scholar
• Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line. Eur. J. Immunol.38(5), 1414–1422 (2008).
   PubMedGoogle Scholar
• Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J. Immunol.164(3), 1514–1520 (2000).
   PubMed Web of Science ®Google Scholar
• Lu J, Marjon KD, Marnell LL et al. Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc. Natl Acad. Sci. USA108(12), 4974–4979 (2011).
   PubMed Web of Science ®Google Scholar
• Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol.155(4), 2185–2193 (1995).
   PubMed Web of Science ®Google Scholar
• Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, Raynes JG. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). Immunology107(2), 252–260 (2002).
   PubMedGoogle Scholar
• Manolov DE, Rocker C, Hombach V, Nienhaus GU, Torzewski J. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa. Arterioscler. Thromb. Vasc. Biol.24(12), 2372–2377 (2004).
   PubMedGoogle Scholar
• Agrawal A, Volanakis JE. Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis. J. Immunol.152(11), 5404–5410 (1994).
   PubMedGoogle Scholar
• Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur. J. Immunol.31(12), 3475–3483 (2001).
   PubMedGoogle Scholar
• Salmon JE, Pricop L. Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum.44(4), 739–750 (2001).
   PubMed Web of Science ®Google Scholar
• Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation103(9), 1194–1197 (2001).
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension44(1), 6–11 (2004).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis203(1), 67–74 (2009).
   PubMedGoogle Scholar
• Trachtman H, Futterweit S, Arzberger C et al. Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. Pediatr. Nephrol.21(5), 619–626 (2006).
   PubMedGoogle Scholar
• Han KH, Hong KH, Park JH et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation109(21), 2566–2571 (2004).
   PubMed Web of Science ®Google Scholar
• Nagai T, Anzai T, Kaneko H et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension57(2), 208–215 (2011).
   PubMedGoogle Scholar
• Nunomura W. C-reactive protein in eel: purification and agglutinating activity. Biochim. Biophys. Acta1076(2), 191–196 (1991).
   PubMedGoogle Scholar
• Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med.178(5), 1629–1636 (1993).
   PubMed Web of Science ®Google Scholar
• Boncler M, Luzak B, Rozalski M, Golanski J, Rychlik B, Watala C. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb. Res.119(2), 209–216 (2007).
   PubMed Web of Science ®Google Scholar
• Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest.100(3), 522–529 (1997).
   PubMed Web of Science ®Google Scholar
• Kindmark CO. In vitro binding of human C-reactive protein by some pathogenic bacteria and zymosan. Clin. Exp. Immunol.11(2), 283–289 (1972).
   PubMedGoogle Scholar
• Diaz Padilla N, Bleeker WK, Lubbers Y et al. Rat C-reactive protein activates the autologous complement system. Immunology109(4), 564–571 (2003).
   PubMedGoogle Scholar
• Boncler M, Rywaniak J, Szymanski J, Potempa LA, Rychlik B, Watala C. Modified C-reactive protein interacts with platelet glycoprotein Ibalpha. Pharmacol. Rep.63(2), 464–475 (2011).
   PubMedGoogle Scholar
• Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler. Thromb. Vasc. Biol.25(10), 2216–2221 (2005).
   PubMedGoogle Scholar
• Yavin EJ, Fridkin M. Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: use of overlapping peptide sequences to identify a unique inhibitor. J. Pept. Res.51(4), 282–289 (1998).
   PubMedGoogle Scholar
• Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J.8(12), 3773–3779 (1989).
   PubMed Web of Science ®Google Scholar
• Yap SH, Moshage HJ, Hazenberg BP et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim. Biophys. Acta1091(3), 405–408 (1991).
   PubMedGoogle Scholar
• Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin. Chem.48, 111–136 (2009).
   PubMed Web of Science ®Google Scholar
• Ramage L, Guy K. Expression of C-reactive protein and heat-shock protein-70 in the lung epithelial cell line A549, in response to PM10 exposure. Inhal. Toxicol.16(6–7), 447–452 (2004).
   PubMed Web of Science ®Google Scholar
• Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int.68(5), 2103–2110 (2005).
   PubMed Web of Science ®Google Scholar
• Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation108(16), 1930–1932 (2003).
   PubMed Web of Science ®Google Scholar
• Jabs WJ, Theissing E, Nitschke M et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation108(12), 1428–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, Mcgeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol.158(3), 1039–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Lu Q, Jin L. Human gingiva is another site of C-reactive protein formation. J. Clin. Periodontol.37(9), 789–796 (2010).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, Mcgeer EG, Mcgeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res.887(1), 80–89 (2000).
   PubMed Web of Science ®Google Scholar
• Mulder SD, Hack CE, Van Der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer’s disease with the use of index values. J. Alzheimers Dis.22(4), 1073–1079 (2010).
   PubMedGoogle Scholar
• Stearman M, Southgate HJ. The use of cytokine and C-reactive protein measurements in cerebrospinal fluid during acute infective meningitis. Ann. Clin. Biochem.31(Pt 3), 255–261 (1994).
   PubMedGoogle Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med.340(6), 448–454 (1999).
   PubMed Web of Science ®Google Scholar
• Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology23(2), 118–124 (1991).
   PubMed Web of Science ®Google Scholar
• Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J. Clin. Invest.61(2), 235–242 (1978).
   PubMed Web of Science ®Google Scholar
• King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am. J. Cardiol.92(11), 1335–1339 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Clin. Chem.49(8), 1353–1357 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin. Chem.50(3), 574–581 (2004).
   PubMed Web of Science ®Google Scholar
• Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem.46(7), 934–938 (2000).
   PubMed Web of Science ®Google Scholar
• Davis EE, Huffman FG. Differences in coronary heart disease risk markers among apparently healthy individuals of African ancestry. J. Natl Med. Assoc.99(6), 658–664 (2007).
   PubMedGoogle Scholar
• Chambers JC, Eda S, Bassett P et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation104(2), 145–150 (2001).
   PubMed Web of Science ®Google Scholar
• Saito I, Sato S, Nakamura M et al. A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) study. Atherosclerosis194(1), 238–244 (2007).
   PubMed Web of Science ®Google Scholar
• Wen J, Liang Y, Wang F et al. Association of C-reactive protein and metabolic syndrome in a rural Chinese population. Clin. Biochem.42(10–11), 976–983 (2009).
   PubMedGoogle Scholar
• Mcdade TW, Rutherford J, Adair L, Kuzawa CW. Early origins of inflammation: microbial exposures in infancy predict lower levels of C-reactive protein in adulthood. Proc. Biol. Sci.277(1684), 1129–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Imhof A, Frohlich M, Loewel H et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin. Chem.49(4), 669–672 (2003).
   PubMed Web of Science ®Google Scholar
• Yamada S, Gotoh T, Nakashima Y et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am. J. Epidemiol.153(12), 1183–1190 (2001).
   PubMed Web of Science ®Google Scholar
• Stork S, Bots ML, Grobbee DE, Van Der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J. Intern. Med.264(3), 245–253 (2008).
   PubMed Web of Science ®Google Scholar
• Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J. Rheumatol.27(10), 2351–2359 (2000).
   PubMed Web of Science ®Google Scholar
• Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol.89(9), 1117–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Tracy RP, Psaty BM, Macy E et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol.17(10), 2167–2176 (1997).
   PubMed Web of Science ®Google Scholar
• Kershaw KN, Mezuk B, Abdou CM, Rafferty JA, Jackson JS. Socioeconomic position, health behaviors, and C-reactive protein: a moderated-mediation analysis. Health Psychol.29(3), 307–316 (2010).
   PubMed Web of Science ®Google Scholar
• Aiello AE, Kaplan GA. Socioeconomic position and inflammatory and immune biomarkers of cardiovascular disease: applications to the Panel Study of Income Dynamics. Biodemography Soc. Biol.55(2), 178–205 (2009).
   PubMed Web of Science ®Google Scholar
• Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am. J. Med.119(2), 166.e117–e128 (2006).
   PubMedGoogle Scholar
• Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med.264(4), 295–314 (2008).
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Macfadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin. Chem.55(2), 305–312 (2009).
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature473(7347), 317–325 (2011).
   PubMed Web of Science ®Google Scholar
• Crawford DC, Yi Q, Smith JD et al. Allelic spectrum of the natural variation in CRP. Hum. Genet.119(5), 496–504 (2006).
   PubMedGoogle Scholar
• Hage FG, Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. Curr. Atheroscler. Rep.11(2), 124–130 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J. Clin. Endocrinol. Metab.88(1), 255–259 (2003).
   PubMed Web of Science ®Google Scholar
• Lakka HM, Lakka TA, Rankinen T et al. The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vascul. Pharmacol.44(5), 377–383 (2006).
   PubMedGoogle Scholar
• Ridker PM, Pare G, Parker A et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am. J. Hum. Genet.82(5), 1185–1192 (2008).
   PubMed Web of Science ®Google Scholar
• Ben-Assayag E, Shenhar-Tsarfaty S, Bova I et al. Triggered C-reactive protein (CRP) concentrations and the CRP gene -717A>G polymorphism in acute stroke or transient ischemic attack. Eur. J. Neurol.14(3), 315–320 (2007).
   PubMedGoogle Scholar
• Bis JC, Heckbert SR, Smith NL et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis198(1), 166–173 (2008).
   PubMed Web of Science ®Google Scholar
• Flex A, Gaetani E, Papaleo P et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke35(10), 2270–2275 (2004).
   PubMed Web of Science ®Google Scholar
• Grocott HP, White WD, Morris RW et al. Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke36(9), 1854–1858 (2005).
   PubMed Web of Science ®Google Scholar
• Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke37(8), 2018–2023 (2006).
   PubMed Web of Science ®Google Scholar
• Lange LA, Carlson CS, Hindorff LA et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA296(22), 2703–2711 (2006).
   PubMed Web of Science ®Google Scholar
• Liu ZZ, Lv H, Gao F et al. Polymorphism in the human C-reactive protein (CRP) gene, serum concentrations of CRP, and the difference between intracranial and extracranial atherosclerosis. Clin. Chim. Acta389(1–2), 40–44 (2008).
   PubMed Web of Science ®Google Scholar
• Miller DT, Zee RY, Suk Danik J et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann. Hum. Genet.69(Pt 6), 623–638 (2005).
   PubMed Web of Science ®Google Scholar
• Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis178(1), 139–145 (2005).
   PubMed Web of Science ®Google Scholar
• Wang Q, Ding H, Tang JR et al. C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population. Acta Pharmacol. Sin.30(3), 291–298 (2009).
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med.359(18), 1897–1908 (2008).
   PubMed Web of Science ®Google Scholar
• Fornage M, Chiang YA, O’Meara ES et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke39(7), 1952–1959 (2008).
   PubMed Web of Science ®Google Scholar
• Morita A, Nakayama T, Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am. J. Hypertens.19(6), 593–600 (2006).
   PubMed Web of Science ®Google Scholar
• Elkind MS. Impact of innate inflammation in population studies. Ann. NY Acad. Sci.1207, 97–106 (2010).
   PubMed Web of Science ®Google Scholar
• Marsik C, Sunder-Plassmann R, Jilma B et al. The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin. Chem.52(10), 1952–1957 (2006).
   PubMedGoogle Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med.336(14), 973–979 (1997).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation98(8), 731–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342(12), 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347(20), 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation97(20), 2007–2011 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA297(6), 611–619 (2007).
   PubMed Web of Science ®Google Scholar
• Cao JJ, Thach C, Manolio TA et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation108(2), 166–170 (2003).
   PubMed Web of Science ®Google Scholar
• Wakugawa Y, Kiyohara Y, Tanizaki Y et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke37(1), 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Makita S, Nakamura M, Satoh K et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis204(1), 234–238 (2009).
   PubMed Web of Science ®Google Scholar
• Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler. Thromb. Vasc. Biol.20(4), 1047–1051 (2000).
   PubMed Web of Science ®Google Scholar
• Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke32(11), 2575–2579 (2001).
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation107(15), 2016–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA293(13), 1609–1616 (2005).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Luna JM, Moon YP et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology73(16), 1300–1307 (2009).
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation108(19), 2317–2322 (2003).
   PubMed Web of Science ®Google Scholar
• Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch. Intern. Med.165(18), 2063–2068 (2005).
   PubMedGoogle Scholar
• Greenland P, O’Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch. Intern. Med.165(21), 2454–2456 (2005).
   PubMedGoogle Scholar
• Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet375(9709), 132–140 (2010).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Nam BH, Wilson PW et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol.22(10), 1662–1667 (2002).
   PubMed Web of Science ®Google Scholar
• Schillinger M, Exner M, Mlekusch W et al. Inflammation and Carotid Artery – Risk for Atherosclerosis Study (ICARAS). Circulation111(17), 2203–2209 (2005).
   PubMed Web of Science ®Google Scholar
• Chapman CM, Beilby JP, Mcquillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke35(7), 1619–1624 (2004).
   PubMed Web of Science ®Google Scholar
• Rerkasem K, Shearman CP, Williams JA et al. C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. Eur. J. Vasc. Endovasc. Surg.23(6), 505–509 (2002).
   PubMedGoogle Scholar
• Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J. Vasc. Surg.38(5), 1018–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Van Dijk EJ, Prins ND, Vermeer SE et al. C-Reactive protein and cerebral small-vessel disease: the Rotterdam Scan study. Circulation112(6), 900–905 (2005).
   PubMed Web of Science ®Google Scholar
• Andersson J, Johansson L, Ladenvall P et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc. Dis.27(6), 544–551 (2009).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N. Engl. J. Med.344(19), 1450–1460 (2001).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease physiopathology? Circulation112(6), 781–785 (2005).
   PubMed Web of Science ®Google Scholar
• Feigin VL, Rinkel GJ, Lawes CM et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke36(12), 2773–2780 (2005).
   PubMed Web of Science ®Google Scholar
• Montaner J, Fernandez-Cadenas I, Molina CA et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke37(5), 1205–1210 (2006).
   PubMed Web of Science ®Google Scholar
• Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke40(7), 2332–2336 (2009).
   PubMed Web of Science ®Google Scholar
• Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke36(10), 2143–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med.166(19), 2073–2080 (2006).
   PubMed Web of Science ®Google Scholar
• Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke30(5), 981–985 (1999).
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Alvarez-Sabin J, Molina CA et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke34(10), 2463–2468 (2003).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke32(1), 133–138 (2001).
   PubMed Web of Science ®Google Scholar
• Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke33(10), 2459–2464 (2002).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke40(10), 3233–3237 (2009).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol.6, 37 (2006).
   PubMedGoogle Scholar
• Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis199(1), 3–11 (2008).
   PubMed Web of Science ®Google Scholar
• Bogaty P, Brophy JM, Boyer L et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch. Int. Med.165(2), 221–226 (2005).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107(3), 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke36(6), 1316–1329 (2005).
   PubMed Web of Science ®Google Scholar
• Alexandrova ML, Danovska MP. Serum C-reactive protein and lipid hydroperoxides in predicting short-term clinical outcome after spontaneous intracerebral hemorrhage. J. Clin. Neurosci.18(2), 247–252 (2011).
   PubMedGoogle Scholar
• Diedler J, Sykora M, Hahn P et al. C-reactive-protein levels associated with infection predict short- and long-term outcome after supratentorial intracerebral hemorrhage. Cerebrovasc. Dis.27(3), 272–279 (2009).
   PubMedGoogle Scholar
• Godoy DA, Papa F, Campi V et al. Relationship between baseline white blood cell and C-reactive protein with mortality in patients with spontaneous intracerebral hemorrhage. J. Neurol. Neurophysiol.1, 104 (2010).
   Google Scholar
• Di Napoli M, Godoy DA, Campi V et al. C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke42(5), 1230–1236 (2011).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420(6917), 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Willcox BJ, Abbott RD, Yano K, Rodriguez BL, Willcox DC, Curb JD. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker. Expert Rev Neurother4(3), 507–518 (2004).
   PubMedGoogle Scholar
• Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res50(Suppl.), S352–S357 (2009).
   Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation102(18), 2165–2168 (2000).
   PubMed Web of Science ®Google Scholar
• Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol.20(9), 2094–2099 (2000).
   PubMed Web of Science ®Google Scholar
• Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation106(12), 1439–1441 (2002).
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Nataf S, Hu XZ, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol.168(11), 5792–5797 (2002).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Wright TT, Jones NR et al. Inhibition of experimental autoimmune encephalomyelitis in human C-reactive protein transgenic mice is FcgammaRIIB dependent. Autoimmune Dis.2011, 484936 (2011).
   Google Scholar
• Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem.286(8), 6272–6279 (2011).
   PubMedGoogle Scholar
• Jones NR, Pegues MA, Mccrory MA et al. Collagen-induced arthritis is exacerbated in C-reactive protein deficient mice. Arthritis Rheum.63(9), 2641–2650 (2011).
   PubMedGoogle Scholar
• Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J. Immunol.147(10), 3445–3451 (1991).
   PubMedGoogle Scholar
• Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J. Immunol.182(3), 1397–1403 (2009).
   PubMedGoogle Scholar
• Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol.139(1–2), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang J, Rui YC, Yang PY, Lu L, Li TJ. C-reactive protein induced expression of adhesion molecules in cultured cerebral microvascular endothelial cells. Life Sci.78(26), 2983–2988 (2006).
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr. Top. Med. Chem.9(14), 1240–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J. Cereb. Blood Flow Metab.24(11), 1214–1218 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature440(7088), 1217–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Craft TK, Glasper ER, Mccullough L et al. Social interaction improves experimental stroke outcome. Stroke36(9), 2006–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Mcgeer PL, Mcgeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J. Neural Transm. Suppl.59, 53–57 (2000).
   PubMedGoogle Scholar
• Godoy DA, Pinero GR, Svampa S, Papa F, Di Napoli M. Early hyperglycemia and intravenous insulin-the rationale and management of hyperglycemia for spontaneous intracerebral hemorrhage patients: is time for change? Neurocrit. Care10(1), 150–153 (2009).
   PubMedGoogle Scholar
• Blake GJ, Ridker PM, Kuntz KM. Potential cost–effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med.114(6), 485–494 (2003).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation107(3), 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Ess SM, Szucs TD. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ital. Heart J.2(3), 181–188 (2001).
   PubMedGoogle Scholar
• Everett BM, Glynn RJ, Macfadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation121(1), 143–150 (2010).
   PubMed Web of Science ®Google Scholar
• De Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin–JUPITER controversy: a critical reappraisal. Arch. Int. Med.170(12), 1032–1036 (2010).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Hammond DJ Jr, Singh SK. Atherosclerosis-related functions of C-reactive protein. Cardiovasc. Hematol. Disord. Drug Targets10(4), 235–240 (2010).
   PubMedGoogle Scholar
• Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation113(17), 2128–2134; discussion 2151 (2006).
   PubMed Web of Science ®Google Scholar
• Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation109(16), 1914–1917 (2004).
   PubMed Web of Science ®Google Scholar
• Barna BP, Deodhar SD, Gautam S, Yen-Lieberman B, Roberts D. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Cancer Res.44(1), 305–310 (1984).
   PubMed Web of Science ®Google Scholar